The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 09, 2018
Filed:
Mar. 15, 2013
Applicant:
H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US);
Inventors:
Assignee:
H. Lee Moffitt Cancer and Research Institute, Inc., Tampa, FL (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); G01N 33/50 (2006.01); G01N 33/569 (2006.01); G01N 33/574 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/5091 (2013.01); C07K 16/2818 (2013.01); C07K 16/3053 (2013.01); G01N 33/56972 (2013.01); G01N 33/5743 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); G01N 2333/70517 (2013.01); G01N 2800/52 (2013.01);
Abstract
Biomarkers are described for predicting the efficacy, risk of relapse, risk of an immune related adverse event (irAE), or combination thereof for a CTLA-4 blockade treatment, such as ipilimumab, in a subject with melanoma. Biomarkers are also described for predicting the efficacy and clinical benefit for a PD-1 blockade treatment, such as a PD-1 blocking antibody, in a subject with melanoma.